Articles by Patricia Van Arnum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Patricia Van Arnum

Fine-Chemical Producers Make Targeted Investments

Contract API manufacturers proceed with select investment in capacity and service additions.
Apr 2, 2013

Contract API manufacturers proceed with select investment in capacity and service additions.

The Weaknesses and Strengths of the Global API Market

Supply-demand fundamentals show strong growth for generic APIs as gains in innovator APIs lag.
Mar 6, 2013

Supply-demand fundamentals show strong growth for generic APIs as gains in innovator APIs lag.

Fine-Chemical Producers Outline Expansion Plans at Informex

Contract API manufacturers and fine-chemical producers proceed with select investment in capacity and service additions.
Mar 6, 2013

Contract API manufacturers and fine-chemical producers proceed with select investment in capacity and service additions.

Pharma Industry Outlines Opportunity for Incremental Innovation to Improve Global Health

Incremental innovation advances medicines by expanding therapeutic classes, increasing the number of available dosing options, discovering new physiological interactions of known medicines, and improving other properties of existing medicines.
Mar 6, 2013

Incremental innovation advances medicines by expanding therapeutic classes, increasing the number of available dosing options, discovering new physiological interactions of known medicines, and improving other properties of existing medicines

Advancing analytical testing and instrumentation for biopharmaceuticals

Instrument manufacturers and testing service providers are offering improved tools to biologic charaterization.
Mar 2, 2013

Instrument manufacturers and testing service providers are offering improved tools to biologic charaterization.

Advances in PAT for Parenteral Drug Manufacturing

Applying quality-by-design and process analytical technology facilitates process understanding and control of various operations in lyophilization.
Mar 2, 2013

Applying quality-by-design and process analytical technology facilitates process understanding and control of various operations in lyophilization.

Navigating the Global Manufacturing Supply Chain

As the strategic value of emerging markets increase, pharmaceutical companies increase their R&D and manufacturing investments.
Mar 2, 2013

As the strategic value of emerging markets increase, pharmaceutical companies increase their R&D and manufacturing investments.

Quality by Design in Excipients

Factors for assessing excipient variability, the associated challenges developers need to address to design and manufacture solid oral drug products, and solutions for such challenges are examined.
Mar 1, 2013

Factors for assessing excipient variability, the associated challenges developers need to address to design and manufacture solid oral drug products, and solutions for such challenges are examined.

Optimizing Facilities Management in the Pharma Industry

In the era of manufacturing capacity rationalizaton, tighter return on assets, and re-alignment of manufacturing assets to meet changing product demand, strategies for cost-effectively managing manufacturing and other facilities become ever-more crucial. A Q&A with UMS Advisory.
Feb 6, 2013

In the era of manufacturing capacity rationalizaton, tighter return on assets, and re-alignment of manufacturing assets to meet changing product demand, strategies for cost-effectively managing manufacturing and other facilities become ever-more crucial. A Q&A with UMS Advisory.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here